Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective?

Annals of Neurology

Volumn 72, Issue 1, 2012, Pages 4-5

  Low, Phillip A ^a   Gilman, Sid ^b  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; FLUORODEOXYGLUCOSE F 18; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;

APOPTOSIS; BLOOD BRAIN BARRIER; DISEASE COURSE; DOUBLE BLIND PROCEDURE; EDITORIAL; HUMAN; INTERNAL CAROTID ARTERY; MESENCHYMAL STEM CELL; MORTALITY; NERVE CELL; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN AGGREGATION; SCORING SYSTEM; SHY DRAGER SYNDROME; VERTEBRAL ARTERY;

HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MULTIPLE SYSTEM ATROPHY; TRANSPLANTATION, AUTOLOGOUS;

EID: 84864444679     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23655     Document Type: Editorial

References (15)

1. Gilman S, Wenning GK, Low PA, et al. Second consensus conference on the diagnosis of multiple system atrophy. Neurology 2008; 71: 670-676.
2. Geser F, Wenning GK, Seppi K, et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 2006; 21: 179-186.
3. Lipp A, Sandroni P, Ahlskog JE, et al. Prospective differentiation of multiple system atrophy from Parkinson's disease, with and without autonomic failure. Arch Neurol 2009; 66: 742-750.
4. Wakabayashi K, Takahashi H,. Cellular pathology in multiple system atrophy. Neuropathology 2006; 26: 338-345. (Pubitemid 44086838)
5. Windisch M, Wolf HJ, Hutter-Paier B, Wronski R,. Is alpha-synuclein pathology a target for treatment of neurodegenerative disorders? Curr Alzheimer Res 2007; 4: 556-561. (Pubitemid 350248391)
6. Rockenstein E, Ubhi K, Inglis C, et al. Neuronal to oligodendroglial alpha-synuclein redistribution in a double transgenic model of multiple system atrophy. Neuroreport 2012; 23: 259-264.
7. Ubhi K, Rockenstein E, Mante M, et al. Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors. J Neurosci 2010; 30: 6236-6246.
8. Lee PH, Kim JW, Bang OY, et al. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 2008; 83: 723-730. (Pubitemid 351556019)
9. Quinn N, Barker RA, Wenning GK,. Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? Clin Pharmacol Ther 2008; 83: 663-665. (Pubitemid 351556024)
10. Lee PH, Lee JE, Kim HS, et al. A randomized trial of mesenchymal stem cells in multiple system atrophy. Ann Neurol 2012; 72: 32-40.
11. Song SK, Lee SK, Lee JJ, et al. Blood-brain barrier impairment is functionally correlated with clinical severity in patients of multiple system atrophy. Neurobiol Aging 2011; 32: 2183-2189.
12. Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev 2009; 18: 683-692.
13. Kraitchman DL, Tatsumi M, Gilson WD, et al. Dynamic imaging of allogeneic mesenchymal stem cells trafficking to myocardial infarction. Circulation 2005; 112: 1451-1461. (Pubitemid 41291771)
14. Guzman R, De Los Angeles A, Cheshier S, et al. Intracarotid injection of fluorescence activated cell-sorted CD49d-positive neural stem cells improves targeted cell delivery and behavior after stroke in a mouse stroke model. Stroke 2008; 39: 1300-1306. (Pubitemid 351440705)
15. Walczak P, Zhang J, Gilad AA, et al. Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia. Stroke 2008; 39: 1569-1574.